Clinical trials: Human Immunodeficiency Virus I Infection
HIV I Infection
Real World Use of Lenacapavir, as an add-on to an Optimized Background Regimen in France
For most people with HIV (PWH), an effective antiretroviral regimen can be devised. However, some PWH have multiple treatment failures due to viral resistance or unacceptable side effects to medication and no longer have durable…
- Trial name
- LENAddON (NCT06799338)
- Testing
- Lenacapavir Injection
- Where
- France
- Volunteers
- 80 people
- Sponsor
- Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida
Hepatitis C Virus Infection, Human Immunodeficiency Virus Infection
A Multipart, Open-label Study to Evaluate the Safety and Efficacy of ABT-450/r/ABT-267 With and Without ABT-333 Coadministered With and Without Ribavirin in Adult With Genotype 1 or 4 Hepatitis C Virus (HCV) Infection and Human Immunodeficiency Virus, Type 1 Coinfection
The primary objectives of this study are to assess the safety of ABT-450/r/ABT-267 with and without ABT-333 coadministered with and without ribavirin (RBV) for 12 and 24 weeks in HCV GT1- or 4-infected participants with HIV-1…
- Conditions
- Hepatitis C Virus Infection, Human Immunodeficiency Virus Infection, Chronic Hepatitis C, Compensated Cirrhosis and Non-cirrhotics
- Trial name
- TURQUOISE-I (NCT01939197)
- Testing
- ABT-450/r/ABT-267, ABT-333, ribavirin
- Volunteers
- 318 people
- Sponsor
- AbbVie
Advanced Malignant Solid Neoplasm, HIV Infection
Cabozantinib S-Malate in Treating Patients With Advanced Solid Tumors and Human Immunodeficiency Virus
This phase I trial studies the side effects and best dose of cabozantinib s-malate in treating patients with solid tumors that have spread to other places in the body and usually cannot be cured or controlled with treatment and…
- Conditions
- Advanced Malignant Solid Neoplasm, HIV Infection, Metastatic Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm
- Trial name
- NCT01822522
- Testing
- Cabozantinib S-malate, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- 20 sites in United States
- Volunteers
- 36 people
- Sponsor
- National Cancer Institute (NCI)
Healthy Subjects, Hepatic Impairment
GSK1349572 Hepatic Impairment Study
GSK1349572 is an integrase inhibitor that is currently in clinical development for the treatment of human immunodeficiency virus (HIV) infection.
- Conditions
- Healthy Subjects, Hepatic Impairment, Infection, Human Immunodeficiency Virus, HIV Infections
- Trial name
- NCT01231529
- Testing
- GSK1349572
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
HIV Infections
A Study of Nystatin in HIV-Infected Patients
To evaluate the clinical toxicity, safety, and potential anti-HIV activity of intravenous nystatin in patients with HIV infection who have completed protocol FDA 103C.
- Trial name
- NCT00002313
- Testing
- Nystatin, Didanosine
- Where
- United States
- Sponsor
- Argus Pharmaceuticals
Sarcoma, Kaposi, HIV Infections
A Study of AZT Plus Human Interferon Alpha in the Treatment of AIDS-Related Kaposi's Sarcoma
To evaluate the safety and toxicity of combination therapy for AIDS-associated Kaposi's sarcoma with zidovudine (AZT) and two kinds of interferon alpha.
- Trial name
- NCT00001113
- Testing
- Interferon alfa-2a, Zidovudine, Interferon alfa-n1
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Kaposi's Sarcoma
PTC299 in Treating Patients With HIV-Related Kaposi Sarcoma
RATIONALE: PTC299 may stop the growth of Kaposi sarcoma by blocking blood flow to the tumor. PURPOSE: This phase I/II trial is studying the side effects and best dose of PTC299 and to see how well it works in treating patients…
- Trial name
- NCT00686842
- Testing
- VEGF inhibitor PTC299, gene expression analysis, polymerase chain reaction
- Where
- 8 sites in United States
- Volunteers
- 17 people
- Sponsor
- AIDS Malignancy Consortium
HIV Infection
Tenofovir Disoproxil Fumarate to Treat Pediatric HIV
This study will test the safety, side effects and antiviral activity of different doses of tenofovir DF in children and adolescents with human immunodeficiency virus (HIV) infection.
- Trial name
- NCT00024986
- Testing
- Tenofovir DF
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
HIV Infections
A Study of the Safety and Effectiveness of a Chickenpox Vaccine in HIV-Infected Children
The purpose of this study is to see if it is safe to give Varivax to HIV-positive children and whether it protects children from infection.
- Trial name
- NCT00000837
- Testing
- Varicella Virus Vaccine (Live)
- Where
- 25 sites in United States
- Volunteers
- 127 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Study of the HIV gp120/NefTat/AS02A Vaccine to Treat Individuals With Chronic HIV-1 Infection on Highly Active Antiretroviral Therapy (HAART)
This study will test the safety and immunogenicity of the gp120/NefTat/AS02A vaccine candidate in individuals with chronic HIV-1 infection successfully treated with HAART.
- Trial name
- NCT00117429
- Testing
- HIV gp120/NefTat/AS02A Vaccine
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Marcus Altfeld, M.D., Ph.D.
HIV-1-infection
Administration of Venetoclax to Promote Apoptosis of HIV-infected Cells and Reduce the Size of the HIV Reservoir Among People Living With HIV on ART
In summary, there is a compelling rationale for investigating venetoclax as an intervention to sensitise virus-expressing cells to apoptosis and thereby reduce the size of the latent HIV reservoir.
- Trial name
- AMBER (NCT05668026)
- Testing
- Venetoclax
- Where
- 2 sites in Australia, Denmark
- Volunteers
- 18 people
- Sponsor
- University of Aarhus
Human Immunodeficiency Virus
A Safety Study Of A Single Vaginal Administration Of P2G12 Antibody In Healthy Female Subjects
The purpose of this study is to assess the safety and tolerability of intravaginal administration of P2G12. 11 subjects will receive P2G12/placebo. Three subjects in Group 1 will receive up to 7mg of P2G12, or placebo.
- Trial name
- NCT01403792
- Testing
- P2G12
- Where
- United Kingdom
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- University of Surrey
HIV Infections
An Open Trial Combining Zidovudine, Interferon-alfa, and Recombinant CD4-IgG With Transplantation of Syngeneic Bone Marrow and Peripheral Blood Lymphocytes From Healthy gp160-Immunized Donors in the Treatment of Patients With HIV Infection
To restore immunologic function and virus-free state in HIV-infected patients. Based on previous studies showing temporary improvement in immune function in HIV-infected patients using peripheral lymphocyte transfers and bone…
- Trial name
- NCT00000647
- Testing
- CD4-IgG, Zidovudine, Interferon alfa-n1
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV I Infection, Injection Pain
Impact of Pain From Injectables Antiretroviral Treatments in HIV-1 Patients Based on the Injection Site (Ventrogluteal or Dorsogluteal) and the Use or Non-use of Virtual Reality Headset
This is a multicenter, randomized, open-label study with a cross-over design. The objective of this project is to compare the intensity of pain induced by injectable antiretroviral (ARV) treatment (Cabotegravir® and Rilpivirine®)…
- Trial name
- VIHINJECT (NCT06834113)
- Testing
- Dorsogluteal intramuscular injection
- Where
- 5 sites in France
- Volunteers
- 120 people
- Sponsor
- Centre Hospitalier Régional d'Orléans
HIV-1-infection
A Study to Evaluate the Safety and Antiviral Activity of Two Human Monoclonal Antibodies (VRC07-523LS and PGT121.414.LS) During Analytic Treatment Interruption in Participants Living With HIV Who Initiated ART During Acute/Early HIV-1 Infection
The purpose of this study is to evaluate the safety, tolerability, and efficacy of combination broadly neutralizing antibodies (bNAbs), to induce HIV-1 control during analytic treatment interruption (ATI).
- Trial name
- NCT06987318
- Testing
- VRC07-523LS, PGT121.414.LS
- Where
- 13 sites in United States, Brazil and 1 more
- Volunteers
- 40 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Evaluating the Safety, Pharmacokinetics, and Antiviral Activity of a Human Monoclonal Antibody (VRC01) in HIV-Infected Adults Undergoing a Brief Treatment Interruption
The purpose of this study was to evaluate the safety, tolerability, pharmacokinetics (PK), and antiviral activity of an antibody (called VRC01) in HIV-infected adults whose HIV was well-controlled with HIV medicines.
- Trial name
- NCT02463227
- Testing
- VRC01
- Where
- 2 sites in United States
- Volunteers
- 14 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
A Phase I Safety and Immunogenicity Trial of UBI Multivalent HIV-1 Peptide Immunogen in HIV-1 Seronegative Human Subjects
To evaluate, in healthy adult volunteers, the safety and immunogenicity of multivalent HIV-1 peptide immunogen, a formulation of HIV-1 gp120 principal neutralizing domain (PND) branched synthetic peptides from 15 viral strains…
- Trial name
- NCT00000795
- Testing
- HIV-1 Peptide Immunogen, Multivalent
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV -1 Infection
A Clinical Trial to Look at the Safety and Immune Responses of the RNA-based Vaccine BNT168 in Adults Living With or Without HIV
This study will test a new ribonucleic acid (RNA)-based vaccine called BNT168 in adults living both with and without human immunodeficiency virus (HIV), to see how safe it is, how well it triggers the body's immune response and…
- Trial name
- NCT07698600
- Testing
- BNT168
- Where
- 4 sites in United States, South Africa
- Volunteers
- 126 people, healthy volunteers welcome
- Sponsor
- BioNTech SE
HIV Infections
Study of the Efficacy and Safety of Apricitabine, a New NRTI, to Treat Drug-resistant HIV Infection
Apricitabine is a new NRTI which is active against drug-resistant HIV. NRTIs are often included as part of patients' treatment, but many HIV-infected patients develop resistance to commonly used NRTIs such as lamivudine (3TC) and…
- Trial name
- NCT00612898
- Testing
- apricitabine, lamivudine
- Where
- 100 sites in United States, Australia and 9 more
- Volunteers
- 239 people
- Sponsor
- Avexa
HIV Infections
The Safety and Effectiveness of Injections of Human Recombinant Interferon-gamma in Patients With AIDS Who Have Taken Zidovudine
To find out which of four doses of (recombinant) human interferon gamma (IFN-G) is most effective in stimulating the white blood cells (monocytes) to fight infection and to see if treatment with IFN-G can strengthen the ability…
- Trial name
- NCT00001112
- Testing
- Zidovudine, Interferon gamma-1b
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)